Selective estrogen receptor modulator - Merck & Co

Drug Profile

Selective estrogen receptor modulator - Merck & Co

Alternative Names: SERM - Merck

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Karo Bio
  • Developer Merck & Co
  • Class
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 10 Jul 2007 Discontinued - Phase-I with second unnamed SERM compound for Undefined women's health indication in USA (PO)
  • 12 Sep 2006 Phase-I clinical trials with second unnamed SERM compound for Undefined women's health indication in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top